These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22558238)

  • 1. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
    Iaffaldano P; Viterbo RG; Paolicelli D; Lucchese G; Portaccio E; Goretti B; Direnzo V; D'Onghia M; Zoccolella S; Amato MP; Trojano M
    PLoS One; 2012; 7(4):e35843. PubMed ID: 22558238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
    Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
    Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis associated fatigue during natalizumab treatment.
    Putzki N; Yaldizli O; Tettenborn B; Diener HC
    J Neurol Sci; 2009 Oct; 285(1-2):109-13. PubMed ID: 19560168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
    Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
    Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
    Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
    J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
    Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L
    Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Rorsman I; Petersen C; Nilsson PC
    Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients.
    Yildiz M; Tettenborn B; Borgwardt S
    Clin Neurol Neurosurg; 2013 Jul; 115(7):902-3. PubMed ID: 23021201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
    Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
    Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.